Amines & Plasticizers Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 17, 2025, 11:07 pm

Competitors of Amines & Plasticizers Ltd

All Competitor Stocks of Amines & Plasticizers Ltd

Quarterly Result

Last Updated: August 19, 2025, 11:50 pm

Below is a detailed analysis of the quarterly data for Amines & Plasticizers Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 140.29 Cr.. The value appears to be declining and may need further review. It has decreased from 165.81 Cr. (Mar 2025) to 140.29 Cr., marking a decrease of 25.52 Cr..
• For Expenses, as of Jun 2025, the value is 127.30 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 144.84 Cr. (Mar 2025) to 127.30 Cr., marking a decrease of 17.54 Cr..
• For Operating Profit, as of Jun 2025, the value is 12.99 Cr.. The value appears to be declining and may need further review. It has decreased from 20.97 Cr. (Mar 2025) to 12.99 Cr., marking a decrease of 7.98 Cr..
• For OPM %, as of Jun 2025, the value is 9.26%. The value appears to be declining and may need further review. It has decreased from 12.65% (Mar 2025) to 9.26%, marking a decrease of 3.39%.
• For Other Income, as of Jun 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 0.18 Cr. (Mar 2025) to 0.08 Cr., marking a decrease of 0.10 Cr..
• For Interest, as of Jun 2025, the value is 1.66 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.57 Cr. (Mar 2025) to 1.66 Cr., marking a decrease of 0.91 Cr..
• For Depreciation, as of Jun 2025, the value is 1.41 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.41 Cr..
• For Profit before tax, as of Jun 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.17 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 7.17 Cr..
• For Tax %, as of Jun 2025, the value is 25.70%. The value appears to be increasing, which may not be favorable. It has increased from 25.39% (Mar 2025) to 25.70%, marking an increase of 0.31%.
• For Net Profit, as of Jun 2025, the value is 7.43 Cr.. The value appears to be declining and may need further review. It has decreased from 12.81 Cr. (Mar 2025) to 7.43 Cr., marking a decrease of 5.38 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.35. The value appears to be declining and may need further review. It has decreased from 2.33 (Mar 2025) to 1.35, marking a decrease of 0.98.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:58 am

Growth

Last Updated: September 5, 2025, 2:16 pm

Balance Sheet

Last Updated: July 25, 2025, 1:54 pm

Below is a detailed analysis of the balance sheet data for Amines & Plasticizers Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
• For Reserves, as of Mar 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 209.00 Cr. (Mar 2024) to 248.00 Cr., marking an increase of 39.00 Cr..
• For Borrowings, as of Mar 2025, the value is 77.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 85.00 Cr. (Mar 2024) to 77.00 Cr., marking a decrease of 8.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 81.00 Cr.. The value appears to be improving (decreasing). It has decreased from 84.00 Cr. (Mar 2024) to 81.00 Cr., marking a decrease of 3.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 416.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 389.00 Cr. (Mar 2024) to 416.00 Cr., marking an increase of 27.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 80.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 80.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 3.00 Cr..
• For Investments, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 305.00 Cr. (Mar 2024) to 335.00 Cr., marking an increase of 30.00 Cr..
• For Total Assets, as of Mar 2025, the value is 416.00 Cr.. The value appears strong and on an upward trend. It has increased from 389.00 Cr. (Mar 2024) to 416.00 Cr., marking an increase of 27.00 Cr..

Notably, the Reserves (248.00 Cr.) exceed the Borrowings (77.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Amines & Plasticizers Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 7.45. This value is within the healthy range. It has increased from 7.24 (Mar 24) to 7.45, marking an increase of 0.21.
• For Diluted EPS (Rs.), as of Mar 25, the value is 7.45. This value is within the healthy range. It has increased from 7.24 (Mar 24) to 7.45, marking an increase of 0.21.
• For Cash EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 8.46, marking an increase of 0.29.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.01. It has increased from 40.00 (Mar 24) to 47.01, marking an increase of 7.01.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.01. It has increased from 40.00 (Mar 24) to 47.01, marking an increase of 7.01.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 120.09. It has increased from 117.60 (Mar 24) to 120.09, marking an increase of 2.49.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 12.77. This value is within the healthy range. It has decreased from 13.05 (Mar 24) to 12.77, marking a decrease of 0.28.
• For PBIT / Share (Rs.), as of Mar 25, the value is 11.76. This value is within the healthy range. It has decreased from 12.12 (Mar 24) to 11.76, marking a decrease of 0.36.
• For PBT / Share (Rs.), as of Mar 25, the value is 9.98. This value is within the healthy range. It has increased from 9.74 (Mar 24) to 9.98, marking an increase of 0.24.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 7.45. This value is within the healthy range. It has increased from 7.24 (Mar 24) to 7.45, marking an increase of 0.21.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.45. This value is within the healthy range. It has increased from 7.24 (Mar 24) to 7.45, marking an increase of 0.21.
• For PBDIT Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has decreased from 11.10 (Mar 24) to 10.63, marking a decrease of 0.47.
• For PBIT Margin (%), as of Mar 25, the value is 9.79. This value is below the healthy minimum of 10. It has decreased from 10.30 (Mar 24) to 9.79, marking a decrease of 0.51.
• For PBT Margin (%), as of Mar 25, the value is 8.30. This value is below the healthy minimum of 10. It has increased from 8.28 (Mar 24) to 8.30, marking an increase of 0.02.
• For Net Profit Margin (%), as of Mar 25, the value is 6.20. This value is within the healthy range. It has increased from 6.15 (Mar 24) to 6.20, marking an increase of 0.05.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.20. This value is below the healthy minimum of 8. It has increased from 6.15 (Mar 24) to 6.20, marking an increase of 0.05.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.85. This value is within the healthy range. It has decreased from 18.09 (Mar 24) to 15.85, marking a decrease of 2.24.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.20. This value is within the healthy range. It has decreased from 26.60 (Mar 24) to 23.20, marking a decrease of 3.40.
• For Return On Assets (%), as of Mar 25, the value is 9.84. This value is within the healthy range. It has decreased from 10.22 (Mar 24) to 9.84, marking a decrease of 0.38.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.04, marking a decrease of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.38 (Mar 24) to 0.29, marking a decrease of 0.09.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.64. It has decreased from 1.76 (Mar 24) to 1.64, marking a decrease of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 2.41, marking an increase of 0.23.
• For Quick Ratio (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.79, marking an increase of 0.25.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.57. This value is within the healthy range. It has increased from 4.87 (Mar 24) to 7.57, marking an increase of 2.70.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.70. This value is below the healthy minimum of 20. It has decreased from 6.90 (Mar 24) to 6.70, marking a decrease of 0.20.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.90. This value is below the healthy minimum of 20. It has decreased from 6.11 (Mar 24) to 5.90, marking a decrease of 0.21.
• For Earning Retention Ratio (%), as of Mar 25, the value is 93.30. This value exceeds the healthy maximum of 70. It has increased from 93.10 (Mar 24) to 93.30, marking an increase of 0.20.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.10. This value exceeds the healthy maximum of 70. It has increased from 93.89 (Mar 24) to 94.10, marking an increase of 0.21.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 7.16. This value is within the healthy range. It has increased from 5.49 (Mar 24) to 7.16, marking an increase of 1.67.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.18. This value is within the healthy range. It has increased from 4.04 (Mar 24) to 5.18, marking an increase of 1.14.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,209.98. It has increased from 954.77 (Mar 24) to 1,209.98, marking an increase of 255.21.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has increased from 1.48 (Mar 24) to 1.83, marking an increase of 0.35.
• For EV / EBITDA (X), as of Mar 25, the value is 17.22. This value exceeds the healthy maximum of 15. It has increased from 13.29 (Mar 24) to 17.22, marking an increase of 3.93.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.41 (Mar 24) to 1.78, marking an increase of 0.37.
• For Retention Ratios (%), as of Mar 25, the value is 93.29. This value exceeds the healthy maximum of 70. It has increased from 93.09 (Mar 24) to 93.29, marking an increase of 0.20.
• For Price / BV (X), as of Mar 25, the value is 4.56. This value exceeds the healthy maximum of 3. It has increased from 4.13 (Mar 24) to 4.56, marking an increase of 0.43.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.41 (Mar 24) to 1.78, marking an increase of 0.37.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness